Anteo Diagnostics (ASX:ADO): Research Note

Anteo Diagnostics (ASX: ADO) is an Australia based biotechnology company that provides scientists in the Life Sciences, In Vitro Diagnostic (IVD), Medical Device and Energy markets with powerful tools developed with its patented core nanotechnology. There are a number of key milestones to focus on in the next 6-12 months which include: a distribution agreement with a major player in the IVD market; and a possible acquisition that will have a profound impact on the company’s profitmaking ability. 

Pharmaxis (ASX:PXS): Research Note 

Pharmaxis is an Australian based pharmaceutical company with a portfolio of products at various stages of development and approval. Recently the company announced its new strategy that is focused on innovation and partnering. A very successful example of implementing this strategy was already announced last week when the company published that Boehringer Ingelheim has exercised its option to acquire the investigational drug PXS4728A, to develop it for the treatment of the liver‐related condition NASH and to prevent its consequences. 

Latest Research

Resverlogix (RVX.TO): Initiating Coverage Report 

Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is the first to test the BET inhibition hypothesis as a new approach for reducing major adverse cardiovascular events (MACE) in high risk diabetes and CKD patients.

uniQure (QURE): Research Note 

uniQure surprised with the news that it has entered into an agreement with Bristol Myers Squibb (BMY) that provides BMY exclusive access to its gene therapy platform for multiple targets in cardiovascular diseases. 

Simavita (ASX:SVA): Research Note 

Simavita Limited (ASX: SVA; TSX-V: SV) is an Australian based medical device company in digital healthcare that has developed an innovative and unique solution for the management of urinary incontinence, with a focus on the elderly. There are a number of key milestones to focus on in the next 6-12 months which include: announcement of new strategic agreements with one or more large aged facility care chains in the US, an agreement with a major European distributor and the further roll out of Simavita’s technology in potentially six more European countries.  

Galapagos (GPLG.BR): Research Note 

Galapagos announced that its JAK1 inhibitor filgotinib (GLPG0634) met its primary and secondary endpoints after 12 weeks of treatment in the socalled DARWIN in moderate to severe RA patients 

antonie van leeuwenhoek

(delft, netherlands 1632-1723):

founding father of modern biotechnology

We are proud our firm is named after one of the founding fathers of modern biotechnology: Antonie van Leeuwenhoek. Antonie van Leeuwenhoek was a Dutch scientist that lived in the 17th century: 'The Dutch Golden Age", a period in Dutch history, roughly spanning the 17th century, in which Dutch trade, science, military, and art were among the most acclaimed in the world. He was a Dutch tradesman and scientist and is commonly known as "the Father of Microbiology", and considered to be the first microbiologist.

He is best known for his work on the improvement of the microscope and for his contributions towards the establishment of microbiology. Using his handcrafted microscopes, he was the first to observe and describe single-celled organisms, which he originally referred to as animalculs,and which are now referred to as micro organisms. He was also the first to record microscopic observations of muscle fibers, bacteria, spermatozoa, and blood flow in capillaries (small blood vessels). Leeuwenhoek did not author any books; his discoveries came to light through correspondence with the Royal Society, which published his letters.


Invion Group (ASX:IVX): Initiating Coverage Report 

Invion Group (ASX:IVX) is an Australian based biotech company focused on the development of treatments for large indications in respiratory disease and autoimmune disease. There are a number of key milestones to focus on in the next several months which include: data from the Phase II oral INV102 in patients undergoing smoking cessation, data from a Phase II trial of INV103 in lupus patients and completion of enrolment of the NIH-funded Phase II trial of INV102 in asthma patients. 


an unbiased and independent view on companies in the global life sciences sector

Van Leeuwenhoeck Institute (VLI) provides institutional investors and other professional investors with independent, un-biased research on the real value of innovative Life Sciences companies. Many institutional and individual investors will not invest in companies lacking independent third-party research coverage, yet few investment banks cover this sector because it requires dedicated expertise.

In spite of the lack of quality knowledge on an industry-wide basis, there is increased demand for life science-specific market research as investors are seeking information about leading companies in the sector in order to make well-informed investment decisions.